ING Groep NV Sells 112 Shares of Humana Inc. (NYSE:HUM)

ING Groep NV decreased its stake in Humana Inc. (NYSE:HUM) by 0.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,103 shares of the insurance provider’s stock after selling 112 shares during the period. ING Groep NV’s holdings in Humana were worth $5,100,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. lifted its stake in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Creative Financial Designs Inc. ADV grew its stake in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the period. Atwood & Palmer Inc. purchased a new stake in Humana in the 3rd quarter worth about $29,000. Hantz Financial Services Inc. purchased a new stake in Humana in the 2nd quarter worth about $35,000. Finally, Family Firm Inc. bought a new stake in Humana in the 2nd quarter valued at about $37,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HUM has been the subject of several recent research reports. UBS Group reduced their target price on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. Oppenheimer reduced their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. JPMorgan Chase & Co. increased their target price on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Wells Fargo & Company reduced their price target on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $315.86.

Humana Price Performance

HUM opened at $275.67 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $33.19 billion, a P/E ratio of 24.42, a PEG ratio of 2.29 and a beta of 0.52. The stock has a 50-day moving average price of $283.00 and a 200-day moving average price of $331.80. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts predict that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.28%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.